Home » Stocks » CLDX

Celldex Therapeutics, Inc. (CLDX)

Stock Price: $26.77 USD 0.28 (1.06%)
Updated May 11, 2021 4:00 PM EDT - Market closed
After-hours: $26.60 -0.17 (-0.64%) May 11, 7:05 PM
Market Cap 1.07B
Revenue (ttm) 5.37M
Net Income (ttm) -63.69M
Shares Out 39.61M
EPS (ttm) -2.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 11
Last Price $26.77
Previous Close $26.49
Change ($) 0.28
Change (%) 1.06%
Day's Open 25.47
Day's Range 23.95 - 27.61
Day's Volume 288,389
52-Week Range 2.20 - 33.23

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Celldex (CLDX) delivered earnings and revenue surprises of -31.25% and -39.38%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 days ago - Zacks Investment Research

HAMPTON, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.

5 days ago - GlobeNewsWire

HAMPTON, N.J., April 12, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the presentation of promising data from the Company's growing bispecific platform at the Americ...

4 weeks ago - GlobeNewsWire

Not at its present valuation, it's not.

1 month ago - The Motley Fool

HAMPTON, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2020.

1 month ago - GlobeNewsWire

The biotech reported interim results from a phase 1b study.

1 month ago - The Motley Fool

--CDX-0159 generally well tolerated to date-- --Conference call to be held at 7:45 a.m. ET today-- HAMPTON, N.J., March 29, 2021 (GLOBE NEWSWIRE) --  Celldex Therapeutics, Inc. (NASDAQ:CLDX) today repor...

1 month ago - GlobeNewsWire

HAMPTON, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the Company's participation in a fireside chat at the H.C. Wainwright Global Life Sciences Conf...

2 months ago - GlobeNewsWire

Celldex Therapeutics Inc (NASDAQ: CLDX) will expand the clinical development of CDX-0159 into prurigo nodularis (PN), a chronic skin disease characterized by the development of hard, intensely itchy (pr...

2 months ago - Benzinga

--Dermatological indication characterized by chronic, intensely itchy nodules; mast cell activation believed to play an important role in amplifying chronic itch and neuroinflammation-- --Potential to e...

2 months ago - GlobeNewsWire

HAMPTON, N.J., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the Company will participate in a fireside chat at the 10th Annual SVB Leerink Global Healt...

2 months ago - GlobeNewsWire

Celldex Therapeutics is a biopharmaceutical company focused on developing monoclonal and bispecific antibody-based therapeutics. Celldex's new pipeline is now made up of 3 Phase 1 immunotherapies/target...

3 months ago - Seeking Alpha

Investors need to pay close attention to Celldex (CLDX) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

HAMPTON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the promotion of Freddy A. Jimenez, Esq. to Senior Vice President and General Counsel, effective...

4 months ago - GlobeNewsWire

These stocks have made investors richer by posting explosive revenue growth or advancing significantly in high-impact programs.

Other stocks mentioned: CODX, CRDF, RVP, VXRT
4 months ago - The Motley Fool

The highest performers of the year are biotechs fighting COVID-19 and cancer. Are they still buys for 2021?

Other stocks mentioned: BNTX, CODX, CRDF, MCRB, MRNA, NSRGY, NVAX ...
4 months ago - The Motley Fool

HAMPTON, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that the first patient has been dosed in its open label clinical trial in cold contact urticaria...

5 months ago - GlobeNewsWire

HAMPTON, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx C...

5 months ago - GlobeNewsWire

-- A gonist anti-CD40 mAb CDX-1140 demonstrates best-in-class potential; additional expansion cohorts initiated-- --Axl and CDX-527 programs highlighted-- HAMPTON, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -...

6 months ago - GlobeNewsWire

Celldex (CLDX) delivered earnings and revenue surprises of -5.88% and 130.35%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

HAMPTON, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2020.

6 months ago - GlobeNewsWire

Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Here's why shares of these drugmakers seem unstoppable this year.

Other stocks mentioned: CRDF
6 months ago - The Motley Fool

Celldex (CLDX) is developing its monoclonal antibody candidate CDX-0159 as a potential treatment of chronic spontaneous urticaria.

6 months ago - Zacks Investment Research

HAMPTON, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened and the first patient has been dosed in its randomized, double-blind ...

6 months ago - GlobeNewsWire

Why Celldex Has Been A Big Winner In 2020

7 months ago - Seeking Alpha

Investors need to pay close attention to Celldex Therapeutics (CLDX) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

HAMPTON, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in Fireside Chats at the Cantor Virtual Global Healthcare C...

8 months ago - GlobeNewsWire

Here we discuss five biotech companies recording impressive growth so far in 2020.

Other stocks mentioned: ALRN, EBS, HZNP, NVAX
8 months ago - Zacks Investment Research

HAMPTON, N.J., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened in its open-label, Phase 1 study of CDX-527 in patients with advanc...

8 months ago - GlobeNewsWire

Celldex Therapeutics' (CLDX) CEO Anthony Marucci on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

--Conference Call and Webcast today at 4:30pm ET-- --Conference Call and Webcast today at 4:30pm ET--

9 months ago - GlobeNewsWire

HAMPTON, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will report second quarter 2020 financial results on Thursday, August 6, 2020 after the U.S. financial markets...

9 months ago - GlobeNewsWire

Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for July 9th

Other stocks mentioned: FCX, GAN
10 months ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Celldex Therapeutics, Inc. (CLDX).

10 months ago - Zacks Investment Research

Here's what pushed up shares of the highest-flying healthcare stocks.

Other stocks mentioned: IDYA, QDEL
10 months ago - The Motley Fool

The market is reacting to large stock purchases from inside and outside the company.

10 months ago - The Motley Fool

HAMPTON, N.J., June 18, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced the closing of its underwritten public offering of 15,384,614 s...

10 months ago - GlobeNewsWire

HAMPTON, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced the pricing of its previously announced underwritten public off...

10 months ago - GlobeNewsWire

Celldex Jumps On CDX-0159 Data

10 months ago - Seeking Alpha

HAMPTON, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced that it is proposing to offer and sell, subject to market condi...

10 months ago - GlobeNewsWire

Celldex Therapeutics Inc (NASDAQ:CLDX) was trading 3% higher from the previous closing price.

10 months ago - Benzinga

Shares of Celldex Therapeutics Inc (NASDAQ:CLDX) moved higher by 1.5% from the previous closing price.

11 months ago - Benzinga

Investors need to pay close attention to Celldex Therapeutics (CLDX) stock based on the movements in the options market lately.

11 months ago - Zacks Investment Research

--Data strongly support expanding development into mast cell driven diseases----Data presented in a late-breaking session at EAACI Annual Congress 2020-- HAMPTON, N.J., June 06, 2020 (GLOBE NEWSWIRE) ...

11 months ago - GlobeNewsWire

Is (CLDX) Outperforming Other Medical Stocks This Year?

11 months ago - Zacks Investment Research

Celldex (CLDX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

Celldex also eligible to receive future milestone payments plus royalties Celldex also eligible to receive future milestone payments plus royalties

1 year ago - GlobeNewsWire

Celldex (CLDX) reported earnings 30 days ago. What's next for the stock?

1 year ago - Zacks Investment Research

About CLDX

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response... [Read more...]

Industry
Biotechnology
IPO Date
Mar 10, 2008
CEO
Anthony Marucci
Employees
123
Stock Exchange
NASDAQ
Ticker Symbol
CLDX
Full Company Profile

Financial Performance

In 2020, CLDX's revenue was $7.42 million, an increase of 107.61% compared to the previous year's $3.57 million. Losses were -$59.78 million, 17.5% more than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for CLDX stock is "Strong Buy." The 12-month stock price forecast is 34.67, which is an increase of 29.51% from the latest price.

Price Target
$34.67
(29.51% upside)
Analyst Consensus: Strong Buy